Loading patent…
AssigneeMassachusetts Institute of Technology
InventorsPaul Chang, Sejal . Vyas, Anthony Leung, Phillip A. Sharp
Estimating the term…
The invention provides methods for treating or decreasing the likelihood of developing a stress-granule related disorder and/or cancer by administering one or more poly-ADP-ribose polymerase (PARP) inhibitors, one or more PARP activators, one or more poly-ADP-ribose glycosylase (PARG) activators, and/or one or more poly-ADP-ribose glycohydrolase ARH3 activators. The invention also provides corresponding methods of decreasing stress granule formation and/or proliferation in a cell or a population of cells. The invention further provides methods of increasing the number of stress granules and proliferation in a cell or a population of cells by administering one or more PARP activators, one or more PARP inhibitors, one or more PARG inhibitors, and/or one or more ARH3 inhibitors. The invention also provides methods for screening for agents for treating or decreasing the likelihood of developing a stress granule-related disorder or cancer, and methods for determining the propensity for developing a stress granule-related disorder or cancer, as well as compositions and kits containing one or more PARP inhibitors, one or more PARP activators, one or more PARG activators, and one or more ARH3 activators.
A method of treating or decreasing the likelihood of developing a stress granule-related disorder in a subject comprising administering to said subject a therapeutically effective amount of one or more poly-ADP-ribose polymerase (PARP) inhibitor(s), one or more poly-ADP ribose glycolase (PARG) activators, and/or one or more PARP11 activators.
A method of treating or decreasing the likelihood of developing cancer in a subject comprising administering to said subject a therapeutically effective amount of one or more poly-ADP-ribose polymerase (PARP) inhibitor(s).
A pharmaceutical composition comprising one or more PARP inhibitor(s), one or more PARG activators, and/or one or more PARP11 activators, wherein said one or more PARP inhibitor(s) selectively decrease the expression and/or one or more activities of one or more PARP(s) selected from the group consisting of PARP5A, PARP12, PARP13 isoform 1 (PARP13.1), PARP13 isoform 2 (PARP13.2), and PARP15.
A pharmaceutical composition comprising one or more PARP inhibitors, wherein said one or more PARP inhibitor(s) selectively decrease the expression and/or one or more activities of one or more PARP(s) selected from the group consisting of PARP1, PARP2, PARP5A, PARP5B, PARP7, PARP8, PARP14, and PARP16.
A method for determining the propensity of a subject to develop a stress granule-related disorder comprising determining the expression and/or one or more activities of one or more of PARP5A, PARP11, PARP12, PARP13.1, PARP13.2, PARP15, PARG, and ARH3 in a subject, wherein an increase in the expression and/or one or more activities of one or more of PARP5A, PARP12, PARP13.1, PARP13.2, and PARP15, and/or a decrease in the expression or one or more activities of PARP11, PARG, or ARH3 indicates an increased propensity to develop a stress granule-related disorder.
A method for determining the propensity of a subject to develop cancer comprising determining the expression and/or one or more activities of one or more of PARP1, PARP2, PARP5A, PARP5B, PARP7, PARP8, PARP14, and PARP16 in a subject, wherein an increase in the expression and/or one or more activities of one or more of PARP1, PARP2, PARP5A, PARP5B, PARP7, PARP8, PARP14, and PARP16 indicates an increased propensity to develop cancer.
Dependencies are inferred from the claim text.